Business Context and Reporting Period
This Form 6-K filing by Prima BioMed Ltd (noting the request metadata references "IMMUTEP Ltd") is dated May 27, 2016. The registrant is a foreign private issuer based in Sydney, Australia. The filing serves as a cover document for several exhibits containing financial data for the half-year ended December 31, 2015, and historical data for Immutep S.A.S. for the period ended December 12, 2014.
Key Financial Metrics
The provided text is a cover sheet and exhibit index; it does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing references the following documents where such data resides:
- Exhibit 99.1: Prima BioMed Ltd Interim Financial Report for the Half-Year Ended 31 December 2015.
- Exhibit 99.2: Prima BioMed Ltd Management's Discussion & Analysis for the Half-Year Ended 31 December 2015.
- Exhibit 99.3: Immutep S.A.S. Financial Statements for the Period Ended December 12, 2014.
- Exhibit 99.4: Unaudited Pro Forma Condensed Combined Financial Information for the 12 Months Ended June 30, 2015 (relating to the acquisition of Immutep S.A.S.).
Specific financial metrics are not present in the source text provided.
Material Changes
The filing indicates a material corporate event: the acquisition of Immutep S.A.S. by Prima BioMed Ltd. Exhibit 99.4 provides pro forma financial information related to this transaction for the 12 months ended June 30, 2015. No specific quantitative changes in financial performance are detailed in the cover text.
Guidance, Outlook, and Risks
The source text does not contain management commentary, forward-looking guidance, risk factors, or contingencies. These details are expected to be found within the referenced exhibits (specifically Exhibit 99.2).
Investor Verification Checklist
- Verify the specific financial performance of Prima BioMed Ltd for the half-year ended December 31, 2015, by reviewing Exhibit 99.1.
- Review the Management's Discussion & Analysis (Exhibit 99.2) for context on the acquisition of Immutep S.A.S. and its impact on operations.
- Examine the Unaudited Pro Forma Condensed Combined Financial Information (Exhibit 99.4) to understand the combined financial position post-acquisition.
- Confirm the discrepancy between the request metadata ("IMMUTEP Ltd") and the filing registrant ("PRIMA BIOMED LTD") to ensure the correct entity is being analyzed.